[在败血性休克个性化策略中的血管活性剂]
Georg Franz Lehner1, Timo Mayerhöfer2, Fabian Perschinka2
1Gemeinsame Einrichtung für Internistische Notfall- und Intensivmedizin, Innere Medizin 1, Department für Innere Medizin, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. georg.lehner@i-med.ac.at.
Medizinische Klinik, Intensivmedizin und Notfallmedizin
|April 24, 2025
概括
优化败血症休克管理涉及定制使用血管活性剂超出北上腺素. 早期,广泛的血管压缩剂策略和向疗法可以改善器官输液和患者的结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
背景情况:
- 败血冲击管理优先考虑血液动力学稳定和器官 perfusion.
- 目前的指导方针推诺阿基因弗林作为一线血管活性剂.
- 对于耐火病例,可以考虑辅助疗法和替代性血管压缩剂.
研究的目的:
- 探索广泛的血管压缩剂在败血症休克中的潜在益处.
- 研究特定血管活性剂在患者亚表型中的作用.
- 评估辅助疗法的疗效,如皮质类固醇和内扩散剂.
主要方法:
- 对使用血管活性剂的现有证据和病理生理学考虑的审查.
- 对压素和血管素II研究的后期数据的分析.
- 考虑心脏功能障碍和心律失常的辅助疗法.
主要成果:
- 早期,补充性血管活性物质可能提供额外的好处.
- 特定的患者亚表型可能对单个血管活性剂有更好的反应.
- 皮质类固醇,内扩剂和β-阻断剂在特定的败血性休克患者中起作用.
结论:
- 特定的血管活性物质在定义的亚表型中有针对性的使用是合理的.
- 一种带有缓解升级的宽频血管压缩器策略显示出有前途.
- 需要进一步的随机对照试验来确认这些策略的有效性.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
720
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
720
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260
Renal Failure: Dose Adjustments
35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35
Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426


